Skip to Content

Trudhesa FDA Approval Status

FDA Approved: No
Brand name: Trudhesa
Generic name: dihydroergotamine mesylate
Previous Name: INP104
Company: Impel NeuroPharma
Treatment for: Migraine, Chronic Migraine

Trudhesa (dihydroergotamine mesylate) is a nasally administered dihydroergotamine (DHE) formulation in development for the acute treatment of migraine headaches.

Development Timeline for Trudhesa

DateArticle
Jan 20, 2021Impel NeuroPharma Announces U.S. Food & Drug Administration Acceptance of New Drug Application for INP104 for the Acute Treatment of Migraine
Nov  9, 2020Impel Neuropharma Announces FDA Submission of New Drug Application for INP104 for the Acute Treatment of Migraine

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.